Colonel William A. Phillips

Add links

ADX-71441 is a GABAB receptor positive allosteric modulator currently being investigated as a potential treatment for anxiety, epilepsy, pain and other conditions.

Therapeutic potential

Addiction

ADX-71441 has been shown to reduce alcohol consumption.[1] This result was observed in both alcohol dependent and non-dependent animals.[2]

There were also trials about nicotine addiction, which showed positive results: ADX-71441 was able to decrease some withdrawal symptoms of nicotine withdrawal.[3]

Anxiety

This compound has also been shown to reduce anxiety in people with PTSD.[4]

Pain

Experiments have shown that this compound was able to decrease hypersensitivity to pain in mice, Guinea pigs and rats.[4]

Tolerance

ADX-71441 has been shown to have less tolerance and side effects than direct GABAB agonists, such as baclofen.[2]

References

  1. ^ "Addex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Chronic Alcohol Dependence". Addex therapeutics. Retrieved 2024-02-03.
  2. ^ a b Augier, Eric; Dulman, Russell S.; Damadzic, Ruslan; Pilling, Andrew; Hamilton, J. Paul; Heilig, Markus (August 2017). "The GABAB Positive Allosteric Modulator ADX71441 Attenuates Alcohol Self-Administration and Relapse to Alcohol Seeking in Rats". Neuropsychopharmacology. 42 (9): 1789–1799. doi:10.1038/npp.2017.53. ISSN 1740-634X. PMC 5520784. PMID 28294133.
  3. ^ "Addex ADX71441 Positive Results in Preclinical Model of Nicotine Addiction". Addex therapeutics. Retrieved 2024-02-03.
  4. ^ a b Kalinichev, Mikhail; Girard, Françoise; Haddouk, Hasnaà; Rouillier, Mélanie; Riguet, Eric; Royer-Urios, Isabelle; Mutel, Vincent; Lütjens, Robert; Poli, Sonia (2017). "The drug candidate, ADX71441, is a novel, potent and selective positive allosteric modulator of the GABAB receptor with a potential for treatment of anxiety, pain and spasticity". Neuropharmacology. 114: 34–47. doi:10.1016/j.neuropharm.2016.11.016. PMID 27889489. S2CID 36606154.